Table 2.
Characteristics of donor, recipient, and transplant factors in the no-steroid group (n=10,157)
| Characteristic | No-Steroid Induction Categories | P Value | |||
|---|---|---|---|---|---|
| IL2-RA | r-ATG | Alemtuzumab | Before IPTW | After IPTW | |
| No. (%) | 1,483 (14.6) | 4,905 (48.3) | 3,769 (37.1) | ||
| Donors | |||||
| Age (yr) | 41.7±11.4 | 41.6±11.5 | 40.6±11.5 | <0.001 | 0.80 |
| Women | 60.9 | 59.7 | 60.8 | 0.51 | 0.93 |
| Race | <0.001 | 1.00 | |||
| White | 71.3 | 71.7 | 65.2 | ||
| Black | 8.6 | 11.0 | 12.2 | ||
| Hispanic | 13.8 | 12.2 | 19.5 | ||
| Other | 6.3 | 5.0 | 3.0 | ||
| Recipients | |||||
| Age (yr) | 50.7±15.1 | 48.5±13.7 | 48.4±13.4 | <0.001 | 0.36 |
| Women | 35.8 | 36.5 | 36.6 | 0.86 | 0.97 |
| Race | <0.001 | 1.00 | |||
| White | 70.1 | 69.5 | 61.6 | ||
| Black | 9.3 | 12.5 | 13.9 | ||
| Hispanic | 13.8 | 12.3 | 20.2 | ||
| Other | 6.8 | 5.7 | 4.5 | ||
| Diabetes mellitus (yes) | 33.0 | 31.3 | 36.7 | <0.001 | 0.97 |
| Cardiovascular disease (yes) | 5.4 | 7.1 | 4.1 | <0.001 | 0.81 |
| Retransplant | 2.0 | 2.5 | 1.9 | <0.001 | 0.97 |
| Dialysis before transplant | <0.001 | 1.00 | |||
| Preemptive | 35.4 | 37.5 | 32.9 | ||
| <1 yr | 26.6 | 28.7 | 29.6 | ||
| 1–3 yr | 29.1 | 24.3 | 27.2 | ||
| >3 yr | 8.9 | 9.4 | 10.3 | ||
| Panel reactive antibody | <0.001 | 0.62 | |||
| <20 | 45.6 | 39.1 | 36.2 | ||
| 20–80 | 3.8 | 2.9 | 3.6 | ||
| >80 | 0.2 | 0.7 | 0.64 | ||
| Missing | 50.4 | 57.3 | 59.5 | ||
| Transplant | |||||
| Weight ratio (donor/recipient) | 1.01±0.33 | 1.00±0.31 | 0.99±0.30 | 0.02 | 0.89 |
| HLA mismatch | <0.001 | 1.00 | |||
| 1 | 6.9 | 4.9 | 5.3 | ||
| 2 | 21.2 | 16.3 | 17.3 | ||
| 3 | 29.9 | 28.7 | 28.2 | ||
| 4 | 14.0 | 17.2 | 17.3 | ||
| 5 | 18.0 | 21.5 | 20.3 | ||
| 6 | 9.9 | 11.4 | 11.6 | ||
| Transplant year | <0.001 | 0.73 | |||
| 2000–2001 | 6.5 | 0.1 | 0.0 | ||
| 2002–2003 | 5.5 | 3.7 | 2.1 | ||
| 2004–2005 | 17.7 | 15.0 | 10.7 | ||
| 2006–2007 | 20.6 | 22.6 | 17.8 | ||
| 2008–2009 | 20.8 | 26.2 | 25.2 | ||
| 2010–2012 | 28.9 | 32.3 | 44.2 | ||
Data are presented as means±SD or percentages unless otherwise indicated. IL2-RA, IL-2 receptor antagonist; r-ATG, rabbit anti-thymocyte globulin; IPTW, inverse probability of treatment weight.